课题基金 / 基金详情

项目摘要

项目成果

Sridhar Mani的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 本R01的中心目标是明确定义新的拮抗剂结合 孕烷X受体(PXR)的药效团。在这样做的过程中,其他目标包括 用于化学探查PXR的无毒唑类拮抗剂的研究进展 不同组织中的活性和表型(S)。在硅胶模型中,参数将 随着我们获得有效和特异的PXR抑制剂,我们将不断改进。这些 然后,模型可以指导新型小分子拮抗剂的开发 来自不同的化学物质。我们的长期目标是最终发展 可作为肿瘤细胞临床调节剂的PXR无毒拮抗剂 增殖和耐药(例如,PXR激活诱导癌细胞增殖 和抗药性)。也希望这些拮抗剂能够增强活性, 并将选择的抗肿瘤药物(例如他莫昔芬、紫杉醇)的毒性降至最低 在人体内观察到的稳态浓度的PXR激动剂)。为此, 我们鉴定并鉴定了两种新的PXR拮抗剂,酮康唑和 Coumestrol,特异性干扰激活的(配体结合)PXR的功能。在……里面 随后的研究表明,酮康唑:(I)与受体结合并破坏 激活的PXR中的辅调节-受体相互作用;(2)不取代激活的药物 来自PXR的配体结合口袋;(III)PXR突变形式的保留拮抗作用 含有配体结合的口袋填充突变体;和(Iv)不能拮抗突变体 含有表面辅调节因子AF-2结合位点变化的PXR形式。因此, 我们已经建立了一个PXR拮抗模型,其中功能中断是 通过受体的变构修饰或通过与 协同调节因子结合。我们现在建议使用结构、分子、 生化和遗传系统来表征PXR导向的机制 拮抗剂酮康唑及其相关化合物抑制受体激活。
英文摘要
Project Summary/Abstract The central goal of this R01 is to focus on explicitly defining novel antagonist binding pharmacophore on Pregnane X Receptor (PXR). In doing so, additional goals include development of non-toxic azole antagonists that would serve to chemically probe PXR activity and phenotype(s) in different tissues. In silico modeling parameters will continuously be improved as we obtain potent and specific PXR inhibitors. These models could then guide the development of novel small molecule antagonists originating from different chemical entities. The long-term goal is to eventually develop non-toxic antagonists of PXR that can be used as clinical modulators of cancer cell proliferation and drug resistance (e.g., PXR activation induces cancer cell proliferation and drug resistance). It is also hoped that these antagonists will enhance the activity, and minimize the toxicity, of select antineoplastic agents (e.g., tamoxifen, paclitaxel are PXR agonist at concentrations observed at steady-state in humans). Towards this end, we have identified and characterized two novel PXR antagonists, ketoconazole and coumestrol, that specifically disrupt the function of activated (ligand-bound) PXR. In subsequent studies, we have shown that ketoconazole: (i) binds to receptor and disrupts coregulator-receptor interactions in activated PXR; (2) does not displace activating drugs from the ligand-binding pocket of PXR; (iii) retained antagonism of mutant forms of PXR containing ligand-binding pocket filling mutants; and (iv) is unable to antagonize mutant forms of PXR containing alterations in the surface coregulator AF-2 binding site. Thus, we have formulated a model for PXR antagonism in which disruption of function is mediated either by allosteric modification of the receptor or by competition with coregulator binding. We now propose to evaluate this model using structural, molecular, biochemical, and genetic systems to characterize the mechanism by which PXR-directed antagonist ketoconazole and related compounds inhibit receptor activation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microbial Metabolite Mimics, PXR and Colitis-Induced Colorectal Cancer
Microbial Metabolite Mimics, PXR and Colitis-Induced Colorectal Cancer
Microbial Metabolite Mimics, PXR and Colitis-Induced Colorectal Cancer
Development of Novel Drugs to Alleviate CPT-11 Toxicity
海外基金